VivoSeq
Oncology

Salivary Gland Carcinoma

22

Pipeline Programs↗

7

Active Trials↗

16

Companies Involved↗

Salivary Gland Carcinoma is an emerging landscape with 22 programs across 16 companies. The most active players are Avyxa, Johnson & Johnson, Suzhou Suncadia Biopharmaceuticals Co., Ltd.. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

6/100

Mech. Concentration

18/100

Completion Rate

75/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

2 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

2 programs

Phase 2Bayer logo

Bayer

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

74%

Small molecule

23 of 31 classified programs — the dominant modality here.

26%ALL OTHERSMonoclonal antibody516%Antibody–drug conjugate310%

Small molecule leads; the ring shows all 31 classified programs, each share of the total. Modality classified for 100% of 31 pipeline programs.

Analysis

Trial Status

12

clinical trials

Active, not recruiting4 · 33%
Completed3 · 25%
Recruiting3 · 25%
Unknown status1 · 8%
Withdrawn1 · 8%

Clinical Trials

Trial Activity

12 trials

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Recruiting·—·Phase 2·NCT04620187·55 enrolled
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Recruiting·PPeking Union Medical College·Phase 2·NCT06145308·39 enrolled
Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma
Recruiting·—·Phase 2·NCT05727410·50 enrolled
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
Active, not recruiting·FFudan University·Phase 2·NCT05924256·88 enrolled
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
Active, not recruiting·National Cancer Center Hospital East·Phase 2·NCT05694819·56 enrolled
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Active, not recruiting·—·Phase 2·NCT05010629·35 enrolled
Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Active, not recruiting·—·Phase 2·NCT03942653·20 enrolled
Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma
Completed·UUNICANCER·Phase 2·NCT02393820·72 enrolled
Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas
Completed·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT02776163·107 enrolled
Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck
Completed·UUNICANCER·Phase 2·NCT03132038·98 enrolled
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Withdrawn·AActuate Therapeutics Inc.·Phase 2·NCT04832438
Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas
Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·N/A·NCT05013515·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)